BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:08 PM
Aug 24, 2007
 |  BC Extra  |  Top Story

EC approves Avastin for NSCLC

The EC approved an MAA from Roche (SWX:ROG) to expand the label of Avastin bevacizumab to include first-line treatment of patients with advanced non-small cell lung cancer in combination with platinum-based chemotherapy.


Read the full 160 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >